ARTICLE SUMMARY:
Evident Vascular has gone back to the drawing board to develop an intravascular ultrasound system designed for the clinical needs of the peripheral vascular interventionalist, with streamlined workflow and AI/machine learning-enabled image interpretation, to address the numerous barriers that have resulted in a low rate of adoption for a clinically valuable tool.
Evident Vascular was founded in 2021 by Vensana Capital, which has committed $35 million to the start-up. In its ongoing successful strategy of supporting interventions for the peripheral vascular market, the medtech investor decided this time to create a company from scratch, to fill an unmet diagnostic need in the space. (See “Is Better IVUS the Missing Link in Peripheral Vascular Disease?” MedTech Strategist, February 2024.)
In the peripheral arterial disease space, the Vensana investment team previously backed TriVascular, which developed a percutaneous endovascular stent graft for abdominal aortic aneurysms (acquired by Endologix); CV Ingenuity and Lutonix, developers of drug-coated balloons for peripheral arterial disease (acquired by Covidien/Medtronic and CR Bard, respectively); and Intact Vascular, which developed the Tack device for the treatment of dissections, with a rare approval for BTK (below the knee) indications (acquired by Philips). In deep venous disease, Vensana’s portfolio companies include Vesper Medical, a venous stent that recently presented best-in-class clinical data, which supported FDA approval (acquired by Philips) and Inari Medical, which, with a venous thrombectomy device, transformed the treatment of venous thrombosis and pulmonary embolism. Inari is now publicly traded with a multibillion-dollar market cap.
